Orgenesis Aims for Nasdaq Relisting with Decentralized Cell Therapy Model
11.02.2026 - 14:53:05
Following its move to the OTCQX Best Market in October 2024, the biotechnology firm Orgenesis is now actively pursuing a return to a Nasdaq listing. The company's strategy hinges on its decentralized cell processing platform, which it believes can strengthen its market position and meet the necessary requirements for an uplisting.
The development of new therapeutic programs remains a critical driver for investor interest. Orgenesis's research pipeline includes projects in immuno-oncology, viral diseases, and metabolic and autoimmune disorders. Progress in clinical and preclinical stages is being closely monitored by the market.
Recently, the company reported positive real-world study data for its CAR-T therapy, ORG-101, used in treating acute lymphoblastic leukemia. Such clinical milestones are viewed as essential for rebuilding market confidence after the exchange segment downgrade. Upcoming financial disclosures will be scrutinized to determine if Orgenesis can secure the necessary funding for both its ongoing research and its planned Nasdaq return. Regulatory interactions concerning its therapeutic candidates will also form a basis for its valuation within the competitive cell and gene therapy sector.
Should investors sell immediately? Or is it worth buying Orgenesis?
A Point-of-Care Production Strategy
Central to the company's plan is a decentralized approach to cell and gene therapy manufacturing. Orgenesis aims to make these advanced treatments more affordable and accessible. Rather than relying on large, centralized production facilities, the company partners directly with hospitals and research centers to enable on-site, point-of-care production.
- Collaborative Framework: The model is built on tight partnerships with academic institutions and clinical sites.
- Operational Core: It focuses on local production and distribution within medical facilities.
- Cost Efficiency: The company utilizes scalable platforms designed to lower manufacturing costs.
The delisting from Nasdaq last year occurred after the company no longer met certain listing requirements. Management has consistently reiterated its intention to relist on the major exchange once it becomes feasible, with the current operational model being a key part of that effort.
Ad
Orgenesis Stock: Buy or Sell?! New Orgenesis Analysis from February 11 delivers the answer:
The latest Orgenesis figures speak for themselves: Urgent action needed for Orgenesis investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 11.
Orgenesis: Buy or sell? Read more here...
